Grostzner J, Kaczmarek I, Mueller M, et al. Calcineurin-inhibitor-free immunosuppression with mycophenolate mofetil and sirolimus after cardiac transplantation is safe and improves renal function significantly: 1 year follow-up. Abstract 449, ATC 2004.
In this study of 30 heart transplant patients data showed that conversion from a CNI-based immunosuppressant regimen to CellCept and sirolimus in patients with chronic kidney failure is safe, preserves graft function and improves kidney function. This may help avoid CNI-related nephrotoxicity, a common problem after heart transplantation, which can lead to increased morbidity and impairment of patients' quality of life.
in adult kidney transplant patients
Abramowicz D, Gafner N, Wijngaard P. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomised study. Abstract 1527, ATC 2004.
In a study of 151 stable renal transplant patients, where CNI was withdrawn from a CellCept-based immunosuppressant regimen, there was no impact on five-year graft and patient survival. Beneficial effects were observed in kidney function, as well as lipid profile, blood pressure and malignancy rate. These data show that CellCept is safe to use long term as part of a low-toxicity immunosuppressant regimen and allows CNI-sparing, thus avoiding associated kidney toxicity, high cholesterol and high blood pressure, which can lead to impaired graft function.
Kessler M, Frimat L, Charpentier B, et al. Renal function evaluation after half dose reduction of Neoral in combination with CellCept in renal transplant patients with altered renal function: preliminary 2 year safety and efficacy results of the MMF REFERENCE study: a randomised, open, multicentre, prospective, controlled study. Abstract 462, ATC 20
'"/>
Contact: Cendrine Banerjee-Quetel
cendrine.banerjee-quetel@ketchum.com
44-207-611-3656
Ketchum
19-May-2004